Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kimball

Showing results (311-320 of 373) with videos related to

Pageof 38
Sort By:
Aging Cell|September 29, 2020
Metabolic dysfunction in human skin: Restoration of mitochondrial integrity and metabolic output by nicotinamide (niacinamide) in primary dermal fibroblasts from older aged donorsJohn E Oblong, Amy Bowman, Holly A Rovito, et al.
American Heart Journal|February 28, 2016
Longer-term impact of cardiology e-consultsJason H Wasfy, Sandhya K Rao, Neil Kalwani, et al.
Journal of General Internal Medicine|August 10, 2016
Targeted Reminder Phone Calls to Patients at High Risk of No-Show for Primary Care Appointment: A Randomized TrialSachin J Shah, Patrick Cronin, Clemens S Hong, et al.
The British Journal of Dermatology|January 23, 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialDiamant Thaçi, Ron Vender, Menno A de Rie, et al.
Journal of the American Academy of Dermatology|October 4, 2016
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trialsAlexandra B Kimball, Thomas Luger, Alice Gottlieb, et al.
Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.
The British Journal of Dermatology|September 16, 2023
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscapeJames G Krueger, John Frew, Gregor B E Jemec, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2019
Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28K A Papp, K Reich, A Blauvelt, et al.
Dermatology and Therapy|December 30, 2022
Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims DataAmit Garg, Haley B Naik, Afsaneh Alavi, et al.
Pageof 38

Showing results (311-320 of 373) with videos related to

Sort By:
Pageof 38
Aging Cell|September 29, 2020
Metabolic dysfunction in human skin: Restoration of mitochondrial integrity and metabolic output by nicotinamide (niacinamide) in primary dermal fibroblasts from older aged donorsJohn E Oblong, Amy Bowman, Holly A Rovito, et al.
American Heart Journal|February 28, 2016
Longer-term impact of cardiology e-consultsJason H Wasfy, Sandhya K Rao, Neil Kalwani, et al.
Journal of General Internal Medicine|August 10, 2016
Targeted Reminder Phone Calls to Patients at High Risk of No-Show for Primary Care Appointment: A Randomized TrialSachin J Shah, Patrick Cronin, Clemens S Hong, et al.
The British Journal of Dermatology|January 23, 2023
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trialDiamant Thaçi, Ron Vender, Menno A de Rie, et al.
Journal of the American Academy of Dermatology|October 4, 2016
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trialsAlexandra B Kimball, Thomas Luger, Alice Gottlieb, et al.
Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.
The British Journal of Dermatology|September 16, 2023
Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscapeJames G Krueger, John Frew, Gregor B E Jemec, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2019
Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28K A Papp, K Reich, A Blauvelt, et al.
Dermatology and Therapy|December 30, 2022
Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims DataAmit Garg, Haley B Naik, Afsaneh Alavi, et al.
Pageof 38